<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Disease-associated inherited deficiencies of complement</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Disease-associated inherited deficiencies of complement</h1>
<div class="graphic"><div class="figure"><div class="ttl">Disease-associated inherited deficiencies of complement</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="12.5%"></colgroup> <colgroup span="2" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Protein</td> <td class="subtitle1">Gene</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Gene OMIM</td> <td class="subtitle1">Laboratory features</td> <td class="subtitle1">Diseases</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Classical pathway</td> </tr> <tr> <td class="indent1" rowspan="3">C1q</td> <td><em>C1QA</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120550" target="_blank">120550</a></td> <td rowspan="3">CH50 = 0; CP defective activation; Inefficient clearance apoptotic cells</td> <td rowspan="3">SLE; infections with encapsulated organisms</td> </tr> <tr> <td><em>C1QB</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120570" target="_blank">120570</a></td> </tr> <tr> <td><em>C1QC</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120575" target="_blank">120575</a></td> </tr> <tr> <td class="indent1" rowspan="2">C1r</td> <td><em>C1R</em></td> <td>AR</td> <td rowspan="2"><a href="https://www.omim.org/entry/613785" target="_blank">613785</a></td> <td>CH50 = 0; CP defective activation</td> <td>SLE; infections with encapsulated organisms; Ehlers-Danlos phenotype</td> </tr> <tr> <td><em>C1R</em></td> <td>AD GOF</td> <td>Normal CH50</td> <td>Hyperpigmentation; skin fragility</td> </tr> <tr> <td class="indent1" rowspan="2">C1s</td> <td><em>C1S</em></td> <td>AR</td> <td rowspan="2"><a href="https://www.omim.org/entry/120580" target="_blank">120580</a></td> <td>CH50 = 0; CP defective activation</td> <td>SLE; infection with encapsulated organisms; Ehlers-Danlos phenotype</td> </tr> <tr> <td><em>C1S</em></td> <td>AD GOF</td> <td>Normal CH50</td> <td>Hyperpigmentation; skin fragility</td> </tr> <tr> <td class="indent1">C2</td> <td><em>C2</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/217000" target="_blank">217000</a></td> <td>CH50 = 0; CP defective activation</td> <td>SLE; infections with encapsulated organisms; atherosclerosis; AMD</td> </tr> <tr> <td class="indent1">C4</td> <td><em>C4A</em> + <em>C4B</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120810" target="_blank">120810</a> + <a href="https://www.omim.org/entry/120820" target="_blank">120820</a></td> <td>CH50 = 0; CP defective activation; biallelic mutations, deletions, or conversions of both C4A and C4B</td> <td>SLE; infections with encapsulated organisms; partial or complete C4A deficiency predisposes to SLE</td> </tr> <tr> <td class="indent1" rowspan="2">C3*</td> <td rowspan="2"><em>C3</em></td> <td>AR LOF</td> <td rowspan="2"><a href="https://www.omim.org/entry/120700" target="_blank">120700</a></td> <td>Both CH50 and AH50 = 0; Defective opsonization and humoral immune response</td> <td>Infections; glomerulonephritis</td> </tr> <tr> <td>AD GOF</td> <td>Increased complement activation</td> <td>aHUS; AMD</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Lectin pathway</td> </tr> <tr> <td class="indent1">MBL</td> <td><em>MBL2</em></td> <td>AD</td> <td><a href="https://www.omim.org/entry/154545" target="_blank">154545</a></td> <td>LP defective activation</td> <td>Increased susceptibility to bacterial infection</td> </tr> <tr> <td class="indent1">MASP-2</td> <td><em>MASP2</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/605102" target="_blank">605102</a></td> <td>LP defective activation</td> <td>Pyogenic infections; inflammatory lung disease; autoimmunity</td> </tr> <tr> <td class="indent1">MASP-3</td> <td><em>MASP1</em><sup>Â¶</sup></td> <td>AR</td> <td><a href="https://www.omim.org/entry/600521" target="_blank">600521</a></td> <td>LP defective activation</td> <td>3MC1</td> </tr> <tr> <td class="indent1">Collectin (CL-L1; CL-K1)</td> <td><em>COLEC11</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/612502" target="_blank">612502</a></td> <td>LP defective activation</td> <td>3MC2</td> </tr> <tr> <td class="indent1">Ficolin 3</td> <td><em>FCN3</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/604973" target="_blank">604973</a></td> <td>LP defective activation</td> <td>Respiratory infections; abscesses</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Alternative pathway</td> </tr> <tr> <td class="indent1" rowspan="2">Factor B</td> <td rowspan="2"><em>CFB</em></td> <td>AD GOF</td> <td rowspan="2"><a href="https://www.omim.org/entry/138470" target="_blank">138470</a></td> <td>AH50 = normal</td> <td>aHUS; AMD</td> </tr> <tr> <td>AR</td> <td>AH50 = 0</td> <td>Infections with encapsulated bacteria</td> </tr> <tr> <td class="indent1">Factor D</td> <td><em>CFD</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/134350" target="_blank">134350</a></td> <td>AH50 = 0</td> <td>Neisserial infections</td> </tr> <tr> <td class="indent1">Properdin</td> <td><em>CFP</em></td> <td>XLR</td> <td><a href="https://www.omim.org/entry/300383" target="_blank">300383</a></td> <td>AH50 = 0; need to employ assay that would require properdin</td> <td>Neisserial infections</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Membrane attack complex</td> </tr> <tr> <td class="indent1">C5</td> <td><em>C5</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120900" target="_blank">120900</a></td> <td>CH50 and AH50 = 0; defective bactericidal activity</td> <td rowspan="6">Neisserial infections</td> </tr> <tr> <td class="indent1">C6</td> <td><em>C6</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/217050" target="_blank">217050</a></td> <td rowspan="5">CH50 and AH50 = 0; defective bactericidal activity</td> </tr> <tr> <td class="indent1">C7</td> <td><em>C7</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/217070" target="_blank">217070</a></td> </tr> <tr> <td class="indent1">C8-alpha</td> <td><em>C8A</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120950" target="_blank">120950</a></td> </tr> <tr> <td class="indent1">C8-beta</td> <td><em>C8B</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120960" target="_blank">120960</a></td> </tr> <tr> <td class="indent1">C8-gamma</td> <td><em>C8G</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120930" target="_blank">120930</a></td> </tr> <tr> <td class="indent1">C9</td> <td><em>C9</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120940" target="_blank">120940</a></td> <td>Reduced CH50 and AH50; deficient bactericidal activity</td> <td>Mild susceptibility to Neisserial infections</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Regulators and receptors</td> </tr> <tr> <td class="indent1">C1 inhibitor</td> <td><em>SERPING1</em></td> <td>AD</td> <td><a href="https://www.omim.org/entry/606860" target="_blank">606860</a></td> <td>Spontaneous activation of complement; consumption of C4/C2; spontaneous activation contact system; generation of bradykinin from high molecular weight kininogen</td> <td>Hereditary angioedema</td> </tr> <tr> <td class="indent1" rowspan="2">Factor I</td> <td rowspan="2"><em>CFI</em></td> <td>AD</td> <td rowspan="2"><a href="https://www.omim.org/entry/217030" target="_blank">217030</a></td> <td rowspan="2">AP activation; C3 consumption</td> <td>AMD; aHUS; preeclampsia</td> </tr> <tr> <td>AR</td> <td>Neisserial infections</td> </tr> <tr> <td class="indent1" rowspan="2">Factor H</td> <td rowspan="2"><em>CFH</em></td> <td>AD</td> <td rowspan="2"><a href="https://www.omim.org/entry/134370" target="_blank">134370</a></td> <td rowspan="2">AP activation; C3 consumption</td> <td>AMD; aHUS; preeclampsia</td> </tr> <tr> <td>AR</td> <td>Neisserial infections</td> </tr> <tr> <td class="indent1" rowspan="2">CD46 (membrane cofactor protein)</td> <td rowspan="2"><em>MCP</em></td> <td>AD LOF</td> <td rowspan="2"><a href="https://www.omim.org/entry/120920" target="_blank">120920</a></td> <td>Excessive AP activation; half normal (approximately 75% of cases) to normal levels on PBC via flow cytometry; decreased C3b/C4b binding</td> <td>aHUS; HELLP syndrome; C3G</td> </tr> <tr> <td>AR</td> <td>Excessive AP activation; CD46 levels absent</td> <td>CVID</td> </tr> <tr> <td class="indent1">CD55</td> <td><em>CD55</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/125240" target="_blank">125240</a></td> <td>Hyperactivation of complement on endothelium</td> <td>CHAPLE disease = protein-losing enteropathy; thrombosis</td> </tr> <tr> <td class="indent1">CD59</td> <td><em>CD59</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/107271" target="_blank">107271</a></td> <td>Erythrocytes highly susceptible to complement-mediated lysis</td> <td>PNH-like, hemolytic anemia; polyneuropathy</td> </tr> <tr> <td class="indent1" rowspan="5">Factor H-related protein deficiencies</td> <td><em>CFHR1</em></td> <td rowspan="5">AR or AD</td> <td><a href="https://www.omim.org/entry/134371" target="_blank">134371</a></td> <td rowspan="5">Normal CH50 and AH50; autoantibodies to factor H; linked deletions of one or more <em>CFHR</em> genes leads to susceptibility to autoantibody-mediated aHUS</td> <td rowspan="5">Older onset aHUS; Neisserial infections</td> </tr> <tr> <td><em>CFHR2</em></td> <td><a href="https://www.omim.org/entry/600889" target="_blank">600889</a></td> </tr> <tr> <td><em>CFHR3</em></td> <td><a href="https://www.omim.org/entry/605336" target="_blank">605336</a></td> </tr> <tr> <td><em>CFHR4</em></td> <td><a href="https://www.omim.org/entry/605337" target="_blank">605337</a></td> </tr> <tr> <td><em>CFHR5</em></td> <td><a href="https://www.omim.org/entry/608593" target="_blank">608593</a></td> </tr> <tr> <td class="subtitle2_left" colspan="6">Receptors</td> </tr> <tr> <td class="indent1">CR2</td> <td><em>CR2</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120650" target="_blank">120650</a></td> <td>Â </td> <td>CVID</td> </tr> <tr> <td class="indent1">CR3 (CD11b/CD18)</td> <td><em>ITGAM</em> + <em>ITGB2</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/120980" target="_blank">120980</a></td> <td rowspan="2">Low levels of CD11/CD18 (LFA-1 or leukocyte function antigen-1) glycoprotein</td> <td rowspan="2">LAD I</td> </tr> <tr> <td class="indent1">CR4 (CD11c/CD18)</td> <td><em>ITGAX</em> + <em>ITGB2</em></td> <td>AR</td> <td><a href="https://www.omim.org/entry/116920" target="_blank">116920</a></td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>AR: autosomal recessive;
    CP: classical pathway;
    AD: autosomal dominant;
    GOF: gain of function;
    LOF: loss of function;
    XLR: X-linked recessive;
    SLE: systemic lupus erythematosus;
    aHUS: atypical hemolytic uremic syndrome;
    LP: lectin pathway;
    AMD: age-related macular degeneration;
    MBL: mannose-binding lectin;
    MASP: mannan-binding lectin-associated protease;
    3MC1: name pooled from identical but four separately named disorders;
    AP: alternative pathway;
    MAC: membrane attack complex;
    PBC: peripheral blood cells;
    HELLP: hemolysis, elevated liver enzymes, and low platelets;
    C3G: C3 glomerulopathy;
    CVID: common variable immunodeficiency;
    CHAPLE disease: CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and severe protein-losing enteropathy;
    CR2: complement receptor 2;
    CR3: complement receptor type 3;
    CR4: complement receptor type 4;
    LAD: leukocyte adhesion deficiency 1.</p>
<p>* C3 is the central component of all three activation pathways.</p>
    
    Â¶ MASP-3 is alternatively spliced from the MASP-1 gene.</div><div class="graphic_reference">Adapted from: Tangye SG, Al-Herz W, Bousfiha A, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2022. Copyright Â© 2022 The Authors. Available at: <a href="https://link.springer.com/article/10.1007/s10875-022-01289-3" target="_blank">https://link.springer.com/article/10.1007/s10875-022-01289-3</a> (Accessed on November 10, 2022). Reproduced under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License 4.0</a>.</div><div id="graphicVersion">Graphic 140105 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
